{
  "id": 3094621,
  "title": "U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis Drug",
  "url": "https://urgent.news/2026/08/24/u-s-registry-data-confirm-liver-risk-with-controversial-vasculitis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-24T18:34:53.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/rheumatology/generalrheumatology/122735"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}